Literature DB >> 16270059

NMR indicates that the small molecule RITA does not block p53-MDM2 binding in vitro.

Marcin Krajewski, Przemyslaw Ozdowy, Loyola D'Silva, Ulli Rothweiler, Tad A Holak.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16270059     DOI： 10.1038/nm1105-1135

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  37 in total

Review 1.  On the relevance of defining protein structures in cancer research.

Authors:  Inés G Muñoz; Franciso J Blanco; Guillermo Montoya
Journal:  Clin Transl Oncol       Date:  2008-04       Impact factor: 3.405

2.  Specific RITA Modification Produces Hyperselective Cytotoxicity While Maintaining In Vivo Antitumor Efficacy.

Authors:  Brian D Peyser; Ann Hermone; Joseph M Salamoun; James C Burnett; Melinda G Hollingshead; Connor F McGrath; Rick Gussio; Peter Wipf
Journal:  Mol Cancer Ther       Date:  2019-07-24       Impact factor: 6.261

Review 3.  The p53 pathway as a target in cancer therapeutics: obstacles and promise.

Authors:  Anna Mandinova; Sam W Lee
Journal:  Sci Transl Med       Date:  2011-01-05       Impact factor: 17.956

Review 4.  Translational approaches targeting the p53 pathway for anti-cancer therapy.

Authors:  Frank Essmann; Klaus Schulze-Osthoff
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

5.  Chk2 mediates RITA-induced apoptosis.

Authors:  J de Lange; M Verlaan-de Vries; A F A S Teunisse; A G Jochemsen
Journal:  Cell Death Differ       Date:  2011-12-09       Impact factor: 15.828

Review 6.  Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunities.

Authors:  Jessica Plati; Octavian Bucur; Roya Khosravi-Far
Journal:  J Cell Biochem       Date:  2008-07-01       Impact factor: 4.429

Review 7.  Awakening guardian angels: drugging the p53 pathway.

Authors:  Christopher J Brown; Sonia Lain; Chandra S Verma; Alan R Fersht; David P Lane
Journal:  Nat Rev Cancer       Date:  2009-12       Impact factor: 60.716

8.  Small-molecule activation of p53 blocks hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in vivo and leads to tumor cell apoptosis in normoxia and hypoxia.

Authors:  Jun Yang; Afshan Ahmed; Evon Poon; Nina Perusinghe; Alexis de Haven Brandon; Gary Box; Melanie Valenti; Suzanne Eccles; Kasper Rouschop; Brad Wouters; Margaret Ashcroft
Journal:  Mol Cell Biol       Date:  2009-02-17       Impact factor: 4.272

9.  Therapeutic considerations for Mdm2: not just a one trick pony.

Authors:  Jason A Lehman; Jacob A Eitel; Christopher N Batuello; Lindsey D Mayo
Journal:  Expert Opin Drug Discov       Date:  2008-11       Impact factor: 6.098

10.  The curcumin analog HO-3867 selectively kills cancer cells by converting mutant p53 protein to transcriptionally active wildtype p53.

Authors:  Esha Madan; Taylor M Parker; Matthias R Bauer; Alisha Dhiman; Christopher J Pelham; Masaki Nagane; M Lakshmi Kuppusamy; Matti Holmes; Thomas R Holmes; Kranti Shaik; Kevin Shee; Salome Kiparoidze; Sean D Smith; Yu-Soon A Park; Jennifer J Gomm; Louise J Jones; Ana R Tomás; Ana C Cunha; Karuppaiyah Selvendiran; Laura A Hansen; Alan R Fersht; Kálmán Hideg; Rajan Gogna; Periannan Kuppusamy
Journal:  J Biol Chem       Date:  2018-01-30       Impact factor: 5.157
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.